NFE2L2 mutation	Lung Non-Small Cell Squamous Cancer	NFE2L2 mutation	Lung Non-Small Cell Squamous Cancer	CB-228 Sensitive: B - Late Trials CB-228 Sensitive : B	CB-228 Sensitive: B - Late Trials CB-228 Sensitive : B
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	CB-228 Sensitive: C2 – Inclusion Criteria CB-228 Sensitive : C2	CB-228 Sensitive: C2 – Inclusion Criteria CB-228 Sensitive : C2
KEAP1 mutation	Lung Non-Small Cell Squamous Cancer	KEAP1 mutation	Lung Non-Small Cell Squamous Cancer	CB-228 Sensitive: C2 – Inclusion Criteria CB-228 Sensitive : C2	CB-228 Sensitive: C2 – Inclusion Criteria CB-228 Sensitive : C2
RICTOR amplification	Gastric Cancer	RICTOR amplification	Gastric Cancer	AZD2014 Sensitive: C2 – Inclusion Criteria AZD2014 Sensitive : C2	AZD2014 Sensitive: C2 – Inclusion Criteria AZD2014 Sensitive : C2
RICTOR amplification	Small Cell Lung Cancer	RICTOR amplification	Small Cell Lung Cancer	AZD2014 Sensitive: C2 – Inclusion Criteria AZD2014 Sensitive : C2	AZD2014 Sensitive: C2 – Inclusion Criteria AZD2014 Sensitive : C2
NFE2L2 mutation	Lung Cancer	NFE2L2 mutation	Lung Cancer	CB-228 Sensitive: C2 – Inclusion Criteria CB-228 Sensitive : C2	CB-228 Sensitive: C2 – Inclusion Criteria CB-228 Sensitive : C2
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	tamoxifen + CB-228 Sensitive: C3 – Early Trials tamoxifen + CB-228 Sensitive : C3	tamoxifen + CB-228 Sensitive: C3 – Early Trials tamoxifen + CB-228 Sensitive : C3
PD-L1 expression	Urothelial Cancer	PD-L1 expression	Urothelial Cancer	durvalumab + AZD2014 Sensitive: C3 – Early Trials durvalumab + AZD2014 Sensitive : C3	durvalumab + AZD2014 Sensitive: C3 – Early Trials durvalumab + AZD2014 Sensitive : C3
NFE2L2 E79K	Lung Non-Small Cell Squamous Cancer	NFE2L2 E79K	Lung Non-Small Cell Squamous Cancer	CB-228 Sensitive: C3 – Early Trials CB-228 Sensitive : C3	CB-228 Sensitive: C3 – Early Trials CB-228 Sensitive : C3
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	CB-228 Sensitive: C3 – Early Trials CB-228 Sensitive : C3	CB-228 Sensitive: C3 – Early Trials CB-228 Sensitive : C3
AKT1 mutation + HR positive	HER2 Negative Breast Cancer	AKT1 mutation + HR positive	HER2 Negative Breast Cancer	CB-228 Sensitive: C3 – Early Trials CB-228 Sensitive : C3	CB-228 Sensitive: C3 – Early Trials CB-228 Sensitive : C3
EWSR1-POU5F1 fusion	Renal Cell Carcinoma	EWSR1-POU5F1 fusion	Renal Cell Carcinoma	CB-228 Sensitive: C3 – Early Trials CB-228 Sensitive : C3	CB-228 Sensitive: C3 – Early Trials CB-228 Sensitive : C3

mTORC2 inhibitor

mTORC2 inhibitor

Associations(45)

Associations
(45)